Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension.

Fadl Elmula, Fadl Elmula M;Jin, Yu;Yang, Wen-Yi;Thijs, Lutgarde;The European Network Coordinating Research On Renal Denervation (ENCOReD) Consortium;et.al.
(2015) Blood Pressure — Vol. 24, n° 5, p. 263-274 (2015)

Files

2015_FadlElmula_Blood_Press.pdf
  • Restricted Access
  • Adobe PDF
  • 610.65 KB

Details

Authors
  • Fadl Elmula, Fadl Elmula M
    Author
  • Jin, Yu
    Author
  • Yang, Wen-Yi
    Author
  • Thijs, Lutgarde
    Author
  • Author
  • Renkin, JeanUCLouvain
    Author
  • The European Network Coordinating Research On Renal Denervation (ENCOReD) Consortium
    Author
Show more
Abstract
Objective. The blood pressure (BP)-lowering effect of renal sympathetic nervous denervation (RDN) in resistant hypertension (rHT) shows large variation among studies. Methods. We meta-analyzed summary statistics of randomized clinical trials on RDN in rHT. For continuous outcomes, we assessed heterogeneity by Cochran's Q test and used random-effect models weighted for the inverse of the variance. We assessed safety by assessing the risk of major adverse events from stratified contingency tables. Results. Of 5652 patients screened in seven trials, 985 (17.4%) qualified and were randomized to control (n = 397) or RDN with SYMPLICITY™ catheters (n = 588). Follow-up was 6 months. In both control and RDN patients, antihypertensive treatment was continued or optimized. At enrolment, age averaged 58.1 years, systolic/diastolic office and 24 h BP 168.5/93.3 mmHg and 151.8/86.1 mmHg, respectively, and estimated glomerular filtration rate (eGFR) 79.3 ml/min/1.73 m2. For BP outcomes, there was heterogeneity among trials. Pooled effects (control minus RDN) were -4.9/-3.5 mmHg (95% confidence interval, -20.9 to 11.1/-8.9 to 1.9) for office BP, -2.8/-1.5 mmHg (-6.5 to 0.8/-3.3 to 0.4) for 24 h BP and 0.81 ml/min/1.73 m2 (-1.69 to 3.30) for eGFR. Removing one trial at a time produced confirmatory results. Adverse events occurred in 7.4% and 9.9% of control and RDN patients, respectively (p = 0.24). Conclusion. In selected rHT patients maintained on antihypertensive drugs, RDN with the SYMPLICITY systems does not significantly decrease BP but is safe. Future trials with next-generation catheters should aim at identifying responders in patients with evidence of sympathetic nervous overactivity.
Affiliations

Citations

Fadl Elmula, F. E. M., Jin, Y., Yang, W.-Y., Thijs, L., Lu, Y.-C., Larstorp, A. C., Persu, A., Sapoval, M., Rosa, J., Widimský, P., Jacobs, L., Renkin, J., Petrák, O., Chatellier, G., Shimada, K., Widimský, J., Kario, K., Azizi, M., Kjeldsen, S. E., et al. (2015). Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 24(5), 263-274. https://doi.org/10.3109/08037051.2015.1058595 (Original work published 2015)